ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

May 21, 2004

In Brief: Henney To Leave NCI For Kansas; Dan Longo Heads BRMP; DeVita To Receive Nervi Award

May 10, 1985

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

October 26, 2012

Underpowered Study Of Evacet Dashes Approval Hopes

September 24, 1999

MEPACT Approved In Europe For Resectable Osteosarcoma

March 27, 2009